These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 15870937)

  • 1. Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma.
    Hiraoka A; Michitaka K; Kumagi T; Kurose K; Uehara T; Hirooka M; Yamashita Y; Kubo Y; Miyaoka H; Iuchi H; Okada S; Ohmoto M; Yamamoto K; Horiike N; Onji M
    Oncol Rep; 2005 Jun; 13(6):1159-63. PubMed ID: 15870937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
    Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.
    Yao FY; Terrault NA; Freise C; Maslow L; Bass NM
    Hepatology; 2001 Aug; 34(2):411-6. PubMed ID: 11481627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
    Kim JH; Park JW; Koh DW; Lee WJ; Kim CM
    Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
    Nagamatsu H; Itano S; Nagaoka S; Akiyoshi J; Matsugaki S; Kurogi J; Tajiri N; Yamasaki S; Koga H; Torimura T; Kumashiro R; Sata M
    Am J Gastroenterol; 2004 Dec; 99(12):2369-75. PubMed ID: 15571585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine treatment of decompensated hepatitis B virus-related cirrhosis.
    Zhang FK
    Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):10-5. PubMed ID: 16481275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
    Hann HW; Fontana RJ; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Gardner SD; Brown N; Griffiths D;
    Liver Transpl; 2003 Jan; 9(1):49-56. PubMed ID: 12514773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
    Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
    Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
    Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
    Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis.
    Bae SH; Yoon SK; Choi JY; Jang JW; Cho SH; Yang JM; Han NI; Ahn BM; Chung KW; Sun HS
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1527-32. PubMed ID: 16174069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series.
    Huang YW; Liu CJ; Lai MY; Lee PH; Tsai MK; Wang SS; Lai MK; Kao JH
    Clin Ther; 2006 Sep; 28(9):1327-34. PubMed ID: 17062306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis.
    Ooga H; Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Kumada H
    J Gastroenterol; 2004 Nov; 39(11):1078-84. PubMed ID: 15580401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.
    Woo HY; Choi JY; Jang JW; You CR; Bae SH; Yoon SK; Yang JM; Choi SW; Han NI; Kim DG
    J Med Virol; 2008 Nov; 80(11):1891-9. PubMed ID: 18814257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
    Tseng PL; Lu SN; Tung HD; Wang JH; Changchien CS; Lee CM
    J Viral Hepat; 2005 Jul; 12(4):386-92. PubMed ID: 15985009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea].
    Jung S; Suh DJ; Park HJ; Park YH; Song HG; Lee HC; Chung YH; Lee YS
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):418-27. PubMed ID: 12506246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of hepatitis B virus infection and inferior vena cava obstruction among patients with liver cirrhosis or hepatocellular carcinoma in Nepal.
    Shrestha SM; Shrestha S; Shrestha A; Tsuda F; Endo K; Takahashi M; Okamoto H
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1921-8. PubMed ID: 17914971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
    Di Marco V; Marzano A; Lampertico P; Andreone P; Santantonio T; Almasio PL; Rizzetto M; Craxì A;
    Hepatology; 2004 Oct; 40(4):883-91. PubMed ID: 15382125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.